A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Trial Profile

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZUMA-1
  • Sponsors Kite Pharma
  • Most Recent Events

    • 12 Feb 2018 Study protocol amended to include phase 2 expanded cohorts.This change was associated with inclusion of safety as primary endpoint for these phase II expanded cohorts.Secondary endpoints also revised accordingly.
    • 22 Dec 2017 Results published in a John Theurer Cancer Center media release.
    • 12 Dec 2017 An updated analysis comparing SCHOLAR-1 outcomes to ZUMA-1 with a minimum follow-up of 12 months and a median follow-up of 15 months, as well as propensity score analyses to compare the studies will be presented.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top